NTC
APLS

NF Trinity Capital’s Apellis Pharmaceuticals APLS Stock Holding History

NF Trinity Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-357,142
Closed -$4.71M – 40
2018
Q4 		$4.71M Hold
357,142
– – 0.77% 31
2018
Q3 		$6.35M Hold
357,142
– – 0.84% 31
2018
Q2 		$7.86M Hold
357,142
– – 1.08% 23
2018
Q1 		$7.9M Hold
357,142
– – 1.09% 21
2017
Q4 		$7.75M Buy
+357,142
New +$5.26M 1.01% 25

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

NF Trinity Capital's APLS Position: Q1 2019 in Review

NF Trinity Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2019, closing a stake of 357,142 shares — an estimated $4.71M sold.

NF Trinity Capital first reported a position in APLS in Q4 2017 and held it in 5 quarters. The position peaked at $7.9M in Q1 2018. 92 funds tracked by Wall St. Rank hold APLS as of Q1 2019.

  • NF Trinity Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • NF Trinity Capital sold 357,142 Apellis Pharmaceuticals shares in Q1 2019, an estimated $4.71M.
  • NF Trinity Capital first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 5 quarters.
  • NF Trinity Capital's Apellis Pharmaceuticals position peaked at $7.9M in Q1 2018.
  • 92 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.